Advisory - Pfizer Canada recalls two lots of EpiPen / EpiPen Jr auto-injectors (0.3 mg and 0.15 mg epinephrine) due to possible device failure

Saturday, April 1, 2017 Medical Gadgets
Email Print This Page Comment
Font : A-A+

OTTAWA, April 1, 2017 /CNW/ -

IssuePfizer Canada, in consultation with Health Canada, is voluntarily recalling

one lot of EpiPen auto-injector and one lot of EpiPen Jr. auto-injector. The recalled devices may contain a defective part that may result in the auto-injector failing to activate or requiring increased force to activate.

This recall is being

conducted following two confirmed international reports of the device failing to activate. There have been no confirmed reports of device failures involving lots distributed in Canada.

EpiPen/EpiPen Jr. auto-injectors are used to deliver an emergency treatment of adrenaline (epinephrine) to patients who are at risk or have a history of serious allergic reactions (anaphylaxis). Failure of the auto-injector to activate may result in patients not receiving the required dose of adrenaline (epinephrine), resulting in the worsening of symptoms of anaphylaxis or anaphylactic reactions, which could be life threatening.

Affected products

  • EpiPen (0.3 mg epinephrine) auto-injector lot 5GU763, expiry date May 2017, 67844 units distributed in Canada
  • EpiPen Jr (0.15 mg epinephrine) auto-injector lot 5GR765, expiry date March 2017, 39503 units distributed in Canada

Who is affected

  • Patients and caregivers who have the affected device

What consumers should do

  • Patients and caregivers should check whether they have the affected device.
  • Contact your pharmacy to arrange return of your EpiPen/EpiPen Jr. device and obtain a replacement as soon as possible.
  • Pfizer Canada is also advising patients and caregivers to keep the affected EpiPen/EpiPen Jr. auto-injectors until a replacement is obtained.
  • In the event that a life-threatening allergic reaction (anaphylaxis) occurs before you can obtain a replacement, use your EpiPen/EpiPen Jr. product as directed by your healthcare provider and then seek emergency medical attention.
  • Speak with your healthcare professional if you are concerned about your health.
  • Contact Pfizer Canada at 1-866-9Pfizer (1-866-973-4937) or CorporateAffairsCanada@pfizer.com for more information on the recall.
  • Report adverse events to health products to Health Canada by calling toll-free at 1?866?234?2345, or by reporting online, by mail or by fax.
  • Report complaints about health products to Health Canada by calling toll-free at 1?800?267?9675, or complete an online complaint form.

What Health Canada is doingHealth Canada is monitoring the company's recall. If new safety information is identified, Health Canada will take appropriate action and inform Canadians.

For more informationStay connected with Health Canada and receive the latest advisories and product recalls using social media tools.

Également disponible en français

 

SOURCE Health Canada



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook